AstraZeneca And Huma On Digital’s Value For Pharma
Executive Summary
Digital tools have long been of interest to pharma for their potential to transform many aspects of drug development, leading to many collaborations between pharma and medtech firms. Here, two companies that have been working together to develop a series of software-based tools for monitoring patients – AstraZeneca and Huma – discuss the value of these partnerships and their potential challenges.
You may also be interested in...
Speaking To Mobiquitiy About The Whats And Hows For Digital Platforms
Health care is undergoing a transformation as more and more treatments become partially-digitized. However, building the platforms required is difficult, meaning many companies call for third-party help. Medtech Insight spoke to one player in this space, Mobiquity, to learn more about the process.
Moving Pharma Execs Out Of The Shadows Is Key To Building Public Trust
2024 Rising Leader, Jack O’Meara, says the industry must ‘promote personalities’ when building new biotech businesses to gain the trust of investors and the public.
Deals Shaping The Industry, February 2024
An interactive look at pharma, medtech, and diagnostics deals made during February 2023. Data courtesy of Biomedtracker.